Kelly M Makielski, Aaron L Sarver, Michael S Henson, Kathleen M Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M Gerard O'Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J Mills, Marc D Schwabenlander, Melissa Wolfe, Michael A Farrar, Gary R Cutter, Joseph S Koopmeiners, Stephen J Russell, Jaime F Modiano, Shruthi Naik
Osteosarcoma is a devastating bone cancer that disproportionally afflicts children, adolescents, and young adults. Standard therapy includes surgical tumor resection combined with multiagent chemotherapy, but many patients still suffer from metastatic disease progression. Neoadjuvant systemic oncolytic virus (OV) therapy has the potential to improve clinical outcomes by targeting primary and metastatic tumor sites and inducing durable antitumor immune responses. Here we describe the first evaluation of neoadjuvant systemic therapy with a clinical-stage recombinant oncolytic vesicular stomatitis virus (VSV), VSV-IFNβ-NIS, in naturally occurring cancer, specifically appendicular osteosarcoma in companion dogs...
December 19, 2023: Molecular Therapy Oncolytics